1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche indication where the high treatment cost justifies the need. While large pharma companies are active in M&A deals, the Mature biotech companies are sticking to its core expertise and venturing into unexplored/new therapy; e.g., GILD in anti-cancer and BIIB for hemophilia. Alike small molecule generics, biosimilar will also get easier and getting similar pace of recognition in coming years; where AMGN, BIIB already started investing in this space and can emerge as a big player in coming years.

REGN, ALXN, and VRTX have transformed into a large-cap mature biotech companies. Whether these three will be acquired or will remain independent and evolve in next giant is still a question, but both the cases present a good investment opportunity for those who willing to hold them for next five years.

GILD has announced the dividend payment and now all eyes will be on CELG and BIIB

Table Of Contents

Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success
In-depth Company Analysis and Reports on
1. Acorda Therapeutics - Neurological Pipeline Getting Bigger
- Key Pipeline Drugs
a. CVT -301 (PhIII, OFF episodes of Parkinson's disease)
b. Dalfampridine (PhIII, post-stroke walking deficits)
c. rHIgM22 (Remyelinating mAb, PhI)
d. Glial Growth Factor 2 (neuregulin, PhI, GGF2)
- Other Programs in the Pipeline - Future Uncertain

2. Alexion Pharma - Pipeline Maturity will witness a Strong 2015 for ALXN
- Asfotase alfa (hypophosphatasia, HPP, R) on Track
- Soliris in PNH and aHUS: Growth to Continue
- SOLIRIS BEYOND PNH AND aHUS
- Beyond Soliris
- Other PhII Programs
- Messenger RNA Therapeutics platform from Moderna

3. Amgen - Focus On New Biologics For Larger Market And Exploiting Biologics' Manufacturing Experience For Biosimilars Gain
- Newly Marketed Product: Future Growth
a. Kyprolis
b. BLINCYTO
- Key Pipeline Products and Development
a. Evolocumab (R, PCSK9 Inhibitor, CVD, SC)
b. Ivabradine (R, Chronic Heart Failure):
c. Talimogene laherparepvec
d. Brodalumab (PhIII, moderate-to-severe plaque psoriasis and psoriatic arthritis, PhII, Asthma)
e. Omecamtiv mecarbil (PhIIb, Heartfailure, licensed from Cytokinetics)
f. Romosozumab (PhIII, co-developed with UCB, Postmenopausal Osteoporosis, PMO)
g. AMG 334 (PhIIb, CGRP receptor mAb)
h. Trebananib (PhIII, Ovarian Cancer):
i. AMG 416 (PhIII, secondary hyperparathyroidism in pt with CKD, velcalcetide)
- Failed in Clinical studies
- Biosimilars in Development
- AMGN's Commercial Strategy

4. Biogen Idec - Growth from Newly Launched Products + Clinical Milestones of Novel Pipeline
- Near-Term Key Pipeline Candidates to Watch
- Hemophilia Franchise Offers Long-Term Opportunity
- Anti-CD20 franchise Continues to Grow through Label Expansion of GAZYVA
- NEUROLOGY: LEADERSHIP IN MS AND PORTFOLIO EXPANSION

5. Celgene - Innovative Strategies for Long Term Gains
- Development In Multiple Myeloma Franchise: Strengthening Pipeline
- Other Oncology Drugs
- Inflammation - Pipeline to start contributing to sales by 2015
- Other Products in Early stage for Long Term Growth

6. Gilead Sciences - Poised to Emerge as a Leader in HCV Treatment
- Sovaldi has made the way, Harvoni to take Lead
- Pipeline: Anti-viral Franchise — HCV
- Antiviral Franchise — HIV
- Cardiovascular Program
- Beyond Anti-Virals- Oncology
- Acquisitions In Last Two Years

7. Regeneron - Late-Stage Pipeline Potential - Accelerator for Further Growth
- Label expansion of E ylea in DME, BRVO, and Myopic CNV indication
- Late-Stage Pipeline
- REGN-Sanofi Collaboration

8. Vertex Pharma - From Large Volume Market to Niche Indications - Transformation has Paid
- Cystic Fibrosis: Success in G551D mutation to Repeat in Larger Population of del508 Mutation
- Small But Meaningful Addition in Other Mutations for KALYDECO monotherapy
- CF BACKGROUND
- Beyond CF Not a Priority

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.